Year All20242023202220212020201920182017201620152014 Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism December 16, 2024 Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes December 12, 2024 Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) December 11, 2024 Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update October 30, 2024 Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call October 23, 2024 Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update July 29, 2024 Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call July 22, 2024 Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions June 24, 2024 Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome) June 3, 2024 Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome) May 28, 2024
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism December 16, 2024
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes December 12, 2024
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) December 11, 2024
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update October 30, 2024
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call October 23, 2024
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update July 29, 2024
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call July 22, 2024
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions June 24, 2024
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome) June 3, 2024
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome) May 28, 2024
